腹腔镜回结肠切除治疗原发克罗恩病何时需加做转流性回肠造口?
该研究基于2005至2015年409例因原发克罗恩病行腹腔镜回结肠切除的患者数据,评估与术后30天围术期脓毒并发症相关的危险因素,并分析加做转流性回肠造口是否与降低并发症相关。结果显示总体并发症率为40.6%,脓毒并发症率为7.6%,使用任何免疫抑制药物是脓毒并发症的唯一独立相关因素,而回肠造口与脓毒并发症无关联。
要点
- 使用任何免疫抑制药物是脓毒并发症的唯一独立相关因素。
- 转流性回肠造口与脓毒并发症无关联,数据无法证明其降低并发症。
- 造口独立相关因素为BMI<18.5 kg/m2、低白蛋白及更长手术时间。
核心结论
- 腹腔镜回结肠切除在部分复杂穿透性疾病包括需联合手术的病例中是安全的。
- 本研究数据无法证明加做转流性回肠造口与降低并发症相关。
研究设计与样本
- 回顾性队列研究,纳入2005至2015年单中心前瞻性数据库中原发克罗恩病行腹腔镜回结肠切除的409例患者。
- 是否行转流性回肠造口由术者决定,采用单因素和多因素分析评估与造口创建及30天围术期脓毒并发症相关的因素。
主要发现
- 409例患者死亡率为零,总体并发症率40.6%,中转率9.3%,脓毒并发症率7.6%。
- 22%的病例创建了转流性造口,其独立相关因素为BMI<18.5 kg/m2(P=0.001)、低血清白蛋白水平(P=0.006)和更长手术时间(P=0.003)。
- 使用任何免疫抑制药物是唯一与脓毒并发症独立相关的变量,总体人群OR 2.7(P=0.036),未造口亚组OR 3.1(P=0.031)。
- 脓毒并发症与回肠造口创建、吻合口构型、穿透性疾病、联合手术、BMI、白蛋白水平及手术时间均无关联。
临床怎么用
- 对于使用免疫抑制药物的克罗恩病患者,行腹腔镜回结肠切除时应警惕脓毒并发症风险。
- 不应仅基于降低脓毒并发症的预期而常规加做转流性回肠造口,需结合BMI、白蛋白及手术时间等因素个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aims of this study were to determine risk factors for morbidity associated with laparoscopic ileocolic resection (LICR) for Crohn's disease (CD) and whether the addition of a diverting ileostomy is associated with reduced morbidity. METHODS: Patients undergoing LICR for primary CD at our institution from 2005 to 2015 included in a prospectively maintained database were assessed. The decision to perform a diverting ileostomy was left at the discretion of the operating surgeon. Demographics, disease-related, and treatment-related variables were evaluated using univariate and multivariate analyses as possible factors associated with diverting ileostomy creation and 30-day perioperative septic complications (anastomotic leaks and/or abscess). Use of any immunosuppressive medication was defined as use of steroids, biologics, and immunomodulators either alone or in combination. RESULTS: For 409 patients, mortality was nil, overall morbidity rate was 40.6%, conversion rate 9.3%, and septic morbidity rate 7.6%. A diverting stoma was created in 22% of cases and was independently associated with BMI < 18.5 kg/m2 (P = 0.001), low serum albumin levels (P = 0.006), and longer operative time (P = 0.003). Use of any immunosuppressive medication was the only variable independently associated with septic complications, both in the overall population (OR 2.7, P = 0.036) and in the subgroup of undiverted patients (OR 3.1, P = 0.031). There was no association between septic morbidity and ileostomy creation, anastomotic configuration, penetrating disease, combined procedures (other resection or strictureplasty), BMI, albumin levels, and operative times. CONCLUSIONS: LICR is safe in selected cases of complex penetrating disease, including when combined procedures are necessary. Our data are unable to prove that a diverting stoma is associated with reduced morbidity.
引用
- Yoon YS, Stocchi L, Holubar S, et al. When should we add a diverting loop ileostomy to laparoscopic ileocolic resection for primary Crohn's disease? Surg Endosc. 2020. PMID: 32468260. doi:10.1007/s00464-020-07670-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。